AlphaRx International Holdings

AlphaRx is a specialty pharmaceutical company that utilized proprietary drug delivery technologies to develop topical versions of established systemic drugs. The company's primary goal was to enhance the safety and efficacy of treatments for inflammation, pain, and fungal infections by delivering medication directly to the affected site. Key programs in its pipeline included Indafree, a topical indomethacin for arthritis, and ARX-111, a topical fluconazole for nail fungus. While the company successfully advanced several candidates into Phase 2 and Phase 3 clinical trials, it ultimately ceased active operations following financial difficulties. Its securities registration was officially revoked by the U.S. Securities and Exchange Commission in 2014. The company was headquartered in Markham, Ontario, and operated a GMP-compliant manufacturing facility.